Frederic J. Reu

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

Brian G.M. Durie, Antje Hoering, Muneer H. Abidi et al. · The Lancet · 2016 · 868 citations · Full text

Hematological Malignancy, Dexamethasone Versus Lenalidomide, Oncology +9

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

David S. Siegel, Thomas G. Martin, Michael Wang et al. · Blood · 2012 · 654 citations · Full text

Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis

Mamta Chawla‐Sarkar, Songa Bae, Frederic J. Reu et al. · Cell Death and Differentiation · 2004 · 358 citations · Full text

Apo2l/trail-induced Apoptosis, Cell Regulation, Medicine +11

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

Shaji Kumar, Natalie S. Callander, Melissa Alsina et al. · Journal of the National Comprehensive Cancer Network · 2017 · 277 citations · Full text

Hematological Malignancy, Plasma Cells, Bone Marrow Failure +14

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

Ravi Vij, Michael Wang, Jonathan L. Kaufman et al. · Blood · 2012 · 254 citations · Full text